Federation des caisses Desjardins du Quebec’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,300	Closed	-$6.28K	–	2632
2021 Q2	$6.28K	Hold	2,300	–	–	﹤0.01%	2179
2021 Q1	$6K	Hold	2,300	–	–	﹤0.01%	2147
2020 Q4	$6.39K	Hold	2,300	–	–	﹤0.01%	2010
2020 Q3	$10.6K	Buy	+2,300	New	+$7.59K	﹤0.01%	1669
2019 Q1	–	Sell	-375	Closed	-$2.99K	–	2142
2018 Q4	$2.99K	Hold	375	–	–	﹤0.01%	1864
2018 Q3	$7.26K	Hold	375	–	–	﹤0.01%	1800
2018 Q2	$6.78K	Hold	375	–	–	﹤0.01%	1848
2018 Q1	$3.99K	Buy	+375	New	+$6.02K	﹤0.01%	1910
2017 Q4	–	Sell	-129	Closed	-$7.09K	–	2196
2017 Q3	$7.09K	Hold	129	–	–	﹤0.01%	1763
2017 Q2	$23.9K	Buy	+129	New	+$22.6K	﹤0.01%	1544

Other funds holding SIOX

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's SIOX Position: Q3 2021 in Review

Federation des caisses Desjardins du Quebec sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q3 2021, closing a stake of 2,300 shares — an estimated $6.28K sold.

Federation des caisses Desjardins du Quebec first reported a position in SIOX in Q2 2017 and held it in 10 quarters. The position peaked at $23.9K in Q2 2017. 56 funds tracked by Wall St. Rank hold SIOX as of Q3 2021.

Federation des caisses Desjardins du Quebec reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 2,300 Sio Gene Therapies Inc. Common Stock shares in Q3 2021, an estimated $6.28K.
Federation des caisses Desjardins du Quebec first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2017 and held it in 10 quarters.
Federation des caisses Desjardins du Quebec's Sio Gene Therapies Inc. Common Stock position peaked at $23.9K in Q2 2017.
56 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2021.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q3 2021, filed 30 Aug 2024.